EBElizabeth A. Brown

Elizabeth A. Brown

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth A. Brown has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Three linked variants have opposing regulatory effects on isovaleryl-CoA dehydrogenase gene expression

    by Elizabeth A Brown, Susan Kales, Michael James Boyle, Joseph Vitti, Dylan Kotliar, Steve Schaffner, Ryan Tewhey, Pardis C Sabeti

    While genome-wide association studies (GWAS) and positive selection scans identify genomic loci driving human phenotypic diversity, functional validation is required to discover the variant(s) responsible. We dissected the IVD gene locus—which encodes the isovaleryl-CoA dehydrogenase enzyme—implicated by selection statistics, multiple GWAS, and clinical genetics as important to function and fitness. We combined luciferase assays, CRISPR/Cas9 genome-editing, massively parallel reporter assays (MPRA), and a deletion tiling MPRA strategy across regulatory loci. We identified three regulatory variants, including an indel, that may underpin GWAS signals for pulmonary fibrosis and testosterone, and that are linked on a positively selected haplotype in the Japanese population. These regulatory variants exhibit synergistic and opposing effects on IVD expression experimentally. Alleles at these variants lie on a haplotype tagged by the variant most strongly associated with IVD expression and metabolites, but with no functional evidence itself. This work demonstrates how comprehensive functional investigation and multiple technologies are needed to discover the true genetic drivers of phenotypic diversity.


  • Open Access

    SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis

    by Bruce A. C. Cree, Rachel Maddux, Amit Bar‐Or, Hans‐Peter Hartung, Amandeep Kaur, Elizabeth Brown, Yicong Li, Yanhua Hu, James K. Sheffield, Diego Silva, et al.

    Objective: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. Methods: DAY-BREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccina-tion) and postvaccination serum samples were included (n = 288). Spike recep-tor binding domain (RBD) antibody levels (seroconversion: =0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: =1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). Results: In fully vaccinated par-ticipants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 expo -sure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lym-phocyte count (ALC), age, body mass index, and sex did not. COVID-19- related AEs were reported in 10% (n = 15/148) of fully vaccinated participants -all were nonserious and not severe; all participants recovered. Interpretation: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.


  • Open Access

    Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial

    by Elizabeth A. Brown, Anne Minnich, Arun J. Sanyal, Rohit Loomba, Shuyan Du, John Schwarz, Richard L. Ehman, Morten Karsdal, Diana J. Leeming, Giovanni Cizza, et al.


  • Open Access

    Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111

    by Aaron E. Lin, William E. Diehl, Yingyun Cai, Courtney L. Finch, Chidiebere Akusobi, Robert N. Kirchdoerfer, Laura Bollinger, Stephen F. Schaffner, Elizabeth A. Brown, Erica Ollmann Saphire, et al.

    For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measured transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.


  • Open Access

    Reporter assays for Ebola virus nucleoprotein oligomerization, virion-like particle budding, and minigenome activity reveal the importance of nucleoprotein amino acid position 111

    by Aaron E. Lin, William E. Diehl, Yingyun Cai, Courtney L. Finch, Chidiebere Akusobi, Robert N. Kirchdoerfer, Laura Bollinger, Stephen F. Schaffner, Elizabeth A. Brown, Erica Ollmann Saphire, et al.

    For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measure transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.

  • Open Access

    Site U1433

    by C.F. Li, J. Lin, D.K. Kulhanek, T. Williams, R. Bao, A. Briais, E.A. Brown, Y. Chen, P.D. Clift, F.S. Colwell, et al.


  • A revision of Lissanthe (Styphelioideae: Ericaceae)

    by Darren M. Crayn, Elizabeth A. Brown, Jocelyn M. Powell

    A revision of the styphelioid genus Lissanthe recognises seven species and two subspecies: L. brevistyla A.R.Bean, L. sapida R.Br., L. strigosa (Sm.) R.Br. subsp. strigosa , L. strigosa subsp. subulata (R.Br.) J.M.Powell. New combinations are made for two species transferred from Leucopogon : Lissanthe rubicunda (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. and Lissanthe pluriloculata (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. Two new species from Western Australia, Lissanthe powelliae D.M.Crayn & E.A.Br. and L. scabra D.M.Crayn & E.A.Br. are described, and Lissanthe sapida is lectotypified. Keys, illustrations and distribution maps are provided for all taxa. Lissanthe as defined here is a strongly supported clade based on analyses of sequence data from two chloroplast loci, the atpB–rbcL intergenic spacer and the matK gene. Potential morphological synapomorphies for Lissanthe include flowers pedicellate above the bracteoles, styles hairy at least at the base, and leaves with an abaxial surface that is grooved longitudinally.


  • Open Access

    Contents Vol. 20, 2002

    by Peter E.T. Isaacs, Michael J.G. Farthing, René Lambert, Jean François Rey, Ann Sommerville, Gerry Livadas, Anthony Axon, Spiros D. Ladas, Peter Malfertheiner, M. Keighley, et al.